Clinical Trial Update: A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs [Phase 2]

View source ↗

Summary

A Phase 2 safety and tolerability trial evaluating CDX-301 with or without plerixafor for stem cell mobilization in matched related donor/recipient sibling tran…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Hodgkin Lymphoma
• Myelodysplastic Syndrome
• Myelogenous Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• CDX-301
• Plerixafor (Plerixafor)

Snippet

Sponsor: Celldex Therapeutics | Conditions: For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling | Phase 2 | Status: TERMINATED